This company is no longer active
Salud financiera de hoja de balance de Zosano Pharma
Salud financiera controles de criterios 4/6
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
Ratio de cobertura de intereses | n/a |
Efectivo | US$13.53m |
Patrimonio | US$14.05m |
Total pasivo | US$12.39m |
Activos totales | US$26.45m |
Actualizaciones recientes sobre salud financiera
Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?
Nov 02Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?
Jun 29Recent updates
Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?
Nov 02Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?
Jun 29Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%
May 26Zosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This Biotech
Apr 30Zosano shares rise on migraine treatment NDA resubmission update
Apr 26Auditors Have Doubts About Zosano Pharma (NASDAQ:ZSAN)
Mar 15Zosano Pharma up 21% following FDA feedback on Qtrypta application; presents Qtrypta data in migraine
Feb 01Zosano Pharma requests FDA meeting for its Qtrypta application
Jan 04Zosano Pharma EPS misses by $0.01
Nov 13Análisis de la situación financiera
Pasivos a corto plazo: ZSAN.Q's short term assets ($15.6M) exceed its short term liabilities ($9.7M).
Pasivo a largo plazo: ZSAN.Q's short term assets ($15.6M) exceed its long term liabilities ($2.7M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ZSAN.Q is debt free.
Reducción de la deuda: ZSAN.Q has no debt compared to 5 years ago when its debt to equity ratio was 39.1%.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ZSAN.Q has less than a year of cash runway based on its current free cash flow.
Pronóstico de cash runway: ZSAN.Q has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.4% each year